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ABSTRACT
A global understanding of the actions of the nuclear
hormone 1a,25-dihydroxyvitamin D3 (1a,25(OH)2D3)
and its vitamin D receptor (VDR) requires a genome-
wide analysis of VDR binding sites. In THP-1 human
monocytic leukemia cells we identified by ChIP-seq
2340 VDR binding locations, of which 1171 and 520
occurred uniquely with and without 1a,25(OH)2D3
treatment, respectively, while 649 were common.
De novo identified direct repeat spaced by 3 nucleo-
tides (DR3)-type response elements (REs) were
strongly associated with the ligand-responsiveness
of VDR occupation. Only 20% of the VDR peaks di-
minishing most after ligand treatment have a DR3-
type RE, in contrast to 90% for the most growing
peaks. Ligand treatment revealed 638 1a,25(OH)2D3
target genes enriched in gene ontology categories
associated with immunity and signaling. From the
408 upregulated genes, 72% showed VDR binding
within 400kb of their transcription start sites
(TSSs), while this applied only for 43% of the 230
downregulated genes. The VDR loci showed consid-
erable variation in gene regulatory scenarios
ranging from a single VDR location near the target
gene TSS to very complex clusters of multiple VDR
locations and target genes. In conclusion, ligand
binding shifts the locations of VDR occupation to
DR3-type REs that surround its target genes and
occur in a large variety of regulatory constellations.
BACKGROUND
The vitamin D receptor (VDR) is an endocrine member of
the nuclear receptor superfamily, since it is activated
already by sub-nanomolar concentrations of its natural
ligand 1a,25-dihydroxyvitamin D3 (1a,25(OH)2D3) (1).
The classical, physiological role of 1a,25(OH)2D3 is the
regulation of calcium and phosphate homeostasis and
bone mineralization (2), but there is both epidemiological
and pre-clinical evidence that VDR ligands have also
anti-proliferative and immuno-modulatory actions (3,4).
VDR is nearly ubiquitously expressed (5) and many cell
types [for example, bone, skin and monocytes (6)] are
capable of metabolizing the main circulating form of
vitamin D, 25-hydroxyvitamin D3 (25(OH)2D3), to
1a,25(OH)2D3 by the enzyme 25(OH)D3-1a-hydroxylase,
encoded by the gene CYP27B1, i.e. 1a,25(OH)2D3 can
have in these tissues both auto- and paracrine roles.
In recent years, an increasing amount of data has shown
a physiological function of 1a,25(OH)2D3 in the immune
system, both in defense and in maintenance of
self-tolerance (7). VDR ligands affect the immune
system in many different ways, but the most important
seems to be the enhanced capacity of innate anti-bacterial
defense and a more tolerogenic proﬁle toward autoim-
mune phenomena (4). One important target cell of
1a,25(OH)2D3 is the monocyte/macrophage, where the
nuclear hormone promotes the anti-bacterial defense
system by inducing the secretion of anti-bacterial
proteins, such as cathelicidin anti-microbial peptide
(CAMP) (8). Importantly, decreased anti-bacterial and
anti-viral defenses are obvious in vitamin D deﬁciency,
and restoration of the vitamin D-sufﬁcient state restores
immune responses (4).
As a member of the nuclear receptor superfamily VDR
acts as a transcription factor that binds to speciﬁc vitamin
D response elements (VDREs) within the regulatory
regions of its primary target genes (1). VDR forms a
heterodimer with retinoid X receptor (RXR), another
member of the nuclear receptor superfamily, and binds
preferentially to VDREs that are formed as direct repeat
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spacing, so-called DR3-type VDREs (9). However, also
other types of VDREs, such as direct repeats with 4
intervening nucleotides (DR4) (10) or everted repeats
(ERs) with a spacer of 6–9 nucleotides (ER6-9) (11,12)
have been reported. Single gene analyses suggest that
VDR target genes often contain multiple functional
VDREs (13–16).
VDR belongs to those nuclear receptors that bind to
their genomic targets already in the absence of ligand.
Under this constellation VDR has been shown to associate
via co-repressor proteins with histone deacetylases and to
repress its target genes (17). Ligand binding induces a con-
formational change that leads to dissociation of
co-repressors and to the association of different types of
co-activator proteins that on one hand lead to chromatin
opening and on the other hand are part of the mediator
complex, which forms a bridge to the basal transcription
machinery associated with the transcription start sites
(TSSs) of primary VDR target genes (18).
Thus far, both single gene and microarray analyses in
various tissues and cells from different species have sug-
gested a long list of VDR target genes. However, the
actions of VDR seem to be highly cell-speciﬁc, since
there is only very little overlap of VDR targets between
the different tissues (19–22). Moreover, such studies have
often been performed at such late time points that they did
not allow distinguishing primary VDR targets from sec-
ondary ones. Recently, Ramagopalan et al. (23) reported
the ﬁrst genome-wide view on VDR locations in human
lymphoblastoid cell lines suggesting 2776 genomic VDR
locations after ligand treatment and 229 target genes.
However, also these data were obtained from a very late
time point (36h after ligand stimulation) and therefore
may not fully represent the primary actions of VDR.
In this study, we used undifferentiated THP-1 human
monocytic leukemia cells as a model system, since they
reﬂect reasonably well the 1a,25(OH)2D3 response of
primary human monocytes (24,25). To gain a
genome-wide view of the primary actions of VDR in
these cells, we determined its genomic binding sites after
40min stimulation with 1a,25(OH)2D3 and in the un-
stimulated state and compared it with the VDR target
genes after 4h ligand treatment. We chose human mono-
cytes as cellular model out of interest in the biological role
of 1a,25(OH)2D3 signaling in the initial events of immune
response. However, the main focus of this study is of
mechanistic nature showing that VDR is associated with
chromatin even in the absence of ligand, but that the
balance of VDR binding shifts from locations that are
gene-centered and lacking classical VDREs to locations
that are more distal to the genes and contain one or
more DR3-type response elements (REs).
MATERIAL AND METHODS
Cell culture
THP-1 human monocytic leukemia cells were grown in
RPMI1640 medium supplemented with 10% fetal calf
serum, 2mM L-glutamine, 0.1mg/ml streptomycin and
100 U/ml penicillin and the cells were kept at 37Ci na
humidiﬁed 95% air/5% CO2 incubator. Prior to mRNA
or chromatin extraction, cells were grown overnight in
phenol red-free medium supplemented with charcoal-
stripped fetal bovine serum. Then, for RNA extractions
cells were treated for 4h with 1a,25(OH)2D3 (Sigma-
Aldrich) or with solvent (ethanol, ﬁnally 0.1%) or for
chromatin immunoprecipitation (ChIP) assays for 40min
with 1a,25(OH)2D3 or left unstimulated.
RNA extraction and cDNA synthesis
Total RNA was extracted using the Mini RNA Isolation
II Kit (Zymo Research, HiSS Diagnostics, Freiburg,
Germany). cDNA synthesis was performed for 60min at
37C using 1mg of total RNA as a template, 100pmol
oligo(dT)18 primers (Eurogentec, Seraing, Belgium),
500mM dNTPs, 40U Ribolock Ribonuclease Inhibitor
and 40U MMuLV reverse transcriptase (Fermentas, St
Leon-Rot, Germany). Prior to real-time quantitative
PCR (qPCR) reaction, the cDNA was diluted 10-fold.
qPCR
qPCR was performed using an ABI 7500 Fast System
(Applied Biosystems, Lennik, Belgium). The reactions
were performed using 250nM of reverse and forward
primers (for sequence see Supplementary Table S1), 4ml
1/10 diluted cDNA template and the ABsolute Q-PCR
SYBR Green Low ROX Mix (Abgene, Westburg,
Leusden, The Netherlands) in a total volume of 20ml. In
the PCR reaction Hotstart Taq polymerase was activated
for 15min at 95C, followed by 40 ampliﬁcation cycles of
30s denaturation at 95C, 30s annealing at primer-speciﬁc
temperatures (Supplementary Table S1) and 40s elong-
ation at 72C and a ﬁnal elongation for 5min at 72C.
PCR product speciﬁcity was monitored using post-PCR
melt curve analysis. Relative expression levels were
determined with the comparative delta threshold cycle
(Ct) method. Ampliﬁcation efﬁciencies of the primer
pairs were taken into account and have been determined
on the basis of a standard curve of a cDNA dilution series
(with two exceptions, all PCR efﬁciencies were between
80% and 120%). Relative expression levels of the target
genes were normalized to the three most stable of 10 tested
internal control genes (b2M, GAPDH, HPRT1). The ex-
pression stability of the control genes was determined by
the geNorm algorithm (26). Brieﬂy, the arithmetic mean of
replicated Ct values for each gene is transformed to a
relative quantity (setting the sample with the highest ex-
pression as calibrator to 1), using the Ct formula
Q=E
Ct=E
(calibratorCtsampleCt) (Q=quantity sample
relative to calibrator sample; E=ampliﬁcation efﬁciency).
For normalization, the relative quantities were divided by
the normalization factor being the geometric mean of the
three reference genes.
Microarray analysis
Total RNA was checked for RNA integrity using a Biorad
Experion electrophoresis station (Biorad, Nazareth,
Belgium) and analyzed on Sentrix Human-6 v2 Expression
BeadChips from Illumina (San Diego, CA, USA) at the
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cols recommended by the manufacturer. Raw microarray
data is available at Gene Expression Omnibus (GEO)
under accession number GSE27270 (SubSeries of
GSE27438). Microarray data analysis was performed
using R statistical software version 2.11 (R Dev Core)
with associated libraries from Bioconductor project
version 2.6 (27). Data was normalized using VST trans-
formation and RSN normalization used as standard
approach for Illumina arrays with the lumi package (28).
Probe sets that were not linked to any known or predicted
human gene were ﬁltered out. Linear Models for
Microarray Data (limma) package (29) using linear
model ﬁtting for statistical testing with empirical Bayes
variance smoothing procedure was applied to detection
of differentially expressed genes. Obtained P-values were
corrected for multiple testing using Benjamini–Hochberg
false discovery rate (FDR) procedure (30). To identify the
biological processes targeted by the 1a,25(OH)2D3-treat-
ment, we used GeneTrail (31) to analyze the enrichment of
up and downregulated VDR target genes into GO
categories using default settings.
ChIP-seq
After ligand or no treatment of THP-1 cells, nuclear
proteins were cross-linked to DNA by adding formalde-
hyde directly to the medium to a ﬁnal concentration of 1%
and incubating at room temperature for 15min on a
rocking platform. Cross-linking was stopped by adding
glycine to a ﬁnal concentration of 0.125M and incubating
at room temperature for 5min on a rocking platform. The
cells were collected by centrifugation and washed twice
with ice cold PBS (140mM NaCl, 2.7mM KCl, 1.5mM
KH2PO4, 8.1mM Na2HPO4·2H2O). The cell pellets were
resuspended in 1ml of lysis buffer (1% SDS, 10mM
EDTA, protease inhibitors, 50mM Tris–HCl, pH 8.1)
and the lysates were sonicated to result in DNA fragments
of 200–400bp. Cellular debris was removed by centrifuga-
tion. Aliquots of 100ml of the lysate were diluted 1:10 in
ChIP dilution buffer (0.01% SDS, 1.1% Triton X-100,
1.2mM EDTA, 167mM NaCl, protease inhibitors,
16.7mM Tris–HCl, pH 8.1) and 1mg of anti-VDR
antibody (ab3508-100, Abcam, Cambridge, UK) or
non-speciﬁc IgG (12-370, Millipore, Temecula, CA,
USA) were added and the samples were incubated for
overnight at 4C on a rotating platform. The
immunocomplexes were collected using 20ml of Magna
ChIP protein A magnetic beads (Millipore) at 4C for
1h with rotation. The beads were washed sequentially
for 5min in rotating platform with 1ml of the following
buffers: low salt wash buffer (0.1% SDS, 1% Triton
X-100, 2mM EDTA, 150mM NaCl, 20mM Tris–HCl,
pH 8.1), high salt wash buffer (0.1% SDS, 1% Triton
X-100, 2mM EDTA, 500mM NaCl, 20mM Tris–HCl,
pH 8.1) and LiCl wash buffer (0.25M LiCl, 1% Nonidet
P-40, 1% sodium deoxycholate, 1mM EDTA, 10mM
Tris–HCl, pH 8.1). Finally, the beads were washed twice
with 1ml TE buffer (1mM EDTA, 10mM Tris–HCl, pH
8.0) and the immune complexes were eluted twice using
250ml elution buffer (1% SDS, 100mM NaHCO3)a t
room temperature for 15min with rotation. The super-
natants were combined and the immune complexes were
reverse cross-linked at 64C overnight in the presence of
proteinase K (Fermentas) in a ﬁnal concentration of
40mg/ml. DNA was extracted with phenol/chloroform/
isoamyl alcohol (25/24/1) and precipitated with 0.1
volumes of 3M sodium acetate, pH 5.2 and 2 volumes
of ethanol using glycogen as carrier. For ChIP-seq ﬁve
individual VDR ChIP samples were pooled and con-
centrated using a SpeedVac. The ChIP templates were
sequenced using a Solexa Gene Analyzer II platform
(Illumina) at 36bp read length using standard manufac-
turer protocols at the Genomics Core Facility in
Heidelberg, Germany. For the validation of the ChIP-
seq data, selected genomic regions containing VDR
peaks were analyzed by quantitative ChIP analysis of in-
dependent samples using Maxima
TM Sybr Green qPCR
Master Mix (Fermentas) and the genomic primers listed
in Supplementary Table S2. In addition to VDR and IgG
antibodies, immunoprecipitation was performed using
1mg of anti-RXR antibody (sc-553, Santa Cruz
Biotechnologies, Santa Cruz, CA, USA). The qPCR reac-
tions were performed with a LightCycler 480 apparatus
(Roche) using the following PCR proﬁle: 10min at
95C, followed by 50 cycles of 30s at 95C, 30s at 58C
and 30s at 72C. The results were normalized with respect
to input. Non-speciﬁc IgG results were subtracted by
using the formula 2
(Cp)*100(speciﬁc antibody)2
(Cp)*
100(non-speciﬁc IgG), where Cp is Cp(immunoprecipitated
DNA)Cp(input) and Cp is the fractional cycle number.
Statistical signiﬁcance was calculated in reference to
non-treated sample using two-tailed Student’s t-test.
ChIP-seq data analysis
Alignment of sequence reads against the human reference
genome version hg19 was done using Bowtie software
version 0.12.2. (32) with the following command line
arguments: bowtie -n 1 -m 1 -e 70 -l 28 -k 1 -t -
p 8 -q -S --best hg19 input_ﬁle_name
output_ﬁle_name. Of note, one Solexa run with 1, 2
and 1 lanes of IgG, unstimulated and ligand-treated VDR
ChIP sample sequencing, respectively, suffered from a
minor post-sequencing processing error at the sequencing
platform that had resulted in an omission of the 16th nu-
cleotide from the large majority of reads. This was cor-
rected for by inserting an N at the missing position in each
read and using two modiﬁed settings in the Bowtie align-
ment (-n 2 -m 3). The short read data publically available
under accession number GSE27437 (SubSeries of
GSE27438) contains the corrected reads. Aligned reads
from multiple lanes were combined per sample. In the
case of ChIP-seq analysis, the common IgG background
read set was scaled so that an individual background was
generated for each VDR ChIP-seq sample by randomly
removing IgG reads such that the read ratio IgG/VDR
became the same for each VDR ChIP-seq sample. The
scaled IgG and un-scaled VDR reads were then converted
to sorted BAM format using SAM tools (33) and subse-
quently also to TDF format using igvtools to allow visu-
alization in the IGV genome browser (34).
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were identiﬁed using MACS program version 1.3.7.1
(35) with the following command line arguments: macs
--pvalue=1e-2 --nomodel --wig -t input_
sample_ﬁle_name -c input_control_ﬁle_name
--tsize=36 --format=BAM --name=analysis_
topic --mfold=13 --shiftsize=250 --bw=250
--verbose=3. A loose initial P-value cutoff was pur-
poseful used to enable catching all true signals with less
regard to possible false positive signals at this early phase
of analysis. Subsequent reﬁnement of MACS peaks was
done using PeakSplitter program version 1.0 (36) with the
following command line arguments: PeakSplitter -p
peak_folder_name -w aligned_read_wig_-
folder_name -o output_folder -c 5 -v 0.6 -f.
An in-house R script was used to calculate fold enrich-
ments (FEs) over IgG, P-values and FDR estimates for
the subpeaks in an identical manner used internally in
MACS 1.3.7.1. Since splitting the original peaks into
several subpeaks may produce large sets of weaker
ﬂanking residual peaks, thus biasing for example the
genomic and FE distributions of the peaks, we kept for
further analysis only those peaks that either had FDR
<1% or were the best subpeak (by FDR) within their
parental MACS peak.
Further data analysis was conducted using an in-house
R pipeline containing tools for identifying peaks
overlapping in two samples, the analysis of genomic dis-
tribution of peaks and the integration of peak and gene
expression data sets. Of note, since there are genomic pos-
itions that cannot be uniquely assigned to the selected
10 types of genomic elements used in the analysis of
peak distributions therein, a prioritization scheme was
employed, where the peaks were uniquely overlapped to
the elements in a step-wise exclusive scheme, starting from
coding elements (UTRs and coding exons), and then
moving to introns and outward from the gene.
Detection of transcription factor binding sites
For the de novo identiﬁcation of the VDR binding consen-
sus sequence within 100bp of the summits of all 2340
FDR <1% VDR peaks we employed the rGADEM
R-package with the following settings: GADEM
(Sequences, genome=Hsapiens, weightType
=1, populationSize=500, numGeneration=20).
Of note, the default settings did not identify the
DR3-like sequence in the full peak set. The resulting can-
didate position weight matrices (PWMs) were then
compared to the set of known PWMs in the JASPAR
database using the MotIV R-package, and their locations
mapped back to the original peaks using in-house
R-scripts. To scan the peak sequences for PWMs repre-
senting different types of DRs and ERs with varying
spacer lengths, we used ‘matrix-scan (quick)’ that is one
of the regulatory sequence analysis tools [RSAT, available
at http://rsat.ulb.ac.be/rsat/ (37)]. For the RSAT scans,
background was modeled at Markov order 2 from the
‘upstream-noorf’ subset of the human genome and a
P-value cutoff of 110
4 was used.
RESULTS
Identiﬁcation of VDR target genes
To identify VDR target genes, THP-1 cells were treated
for 4h with either vehicle (ethanol) or 1a,25(OH)2D3 and
collected for the extraction of total RNA that was sub-
jected to gene expression microarray analysis. We chose
the 4h time point as a compromise to obtain reasonable
mRNA up or downregulation of VDR target genes, the
majority of which still can be considered as primary
targets. Statistically signiﬁcant effect on gene expression
levels (adjusted P<0.05) was detected for transcripts
representing 638 separate Ensembl genes (604 separate
RefSeq gene symbols), out of which 408 (384)
were upregulated and 230 (221) downregulated
(Supplementary Table S3). The broad expression range
of these 638 genes is indicated in Supplementary Figure
S1A. In addition to the larger number of affected genes,
also the magnitude of change was higher for the
upregulated set of VDR target genes (maximal
upregulation 6.65-fold), compared to the downregulated
set (maximal downregulation 1.48-fold). Validation of 43
selected genes on independent samples by qPCR showed a
high correlation (r=0.889, P<1.810
14) to the micro-
array results across a wide range of fold changes
(Supplementary FigureS1B). The validation results of
ﬁve upregulated immunity-related genes CAMP, CD14,
SP100, LRRCA8 and CD93 and a downregulated
immunity-related gene HSH2D are shown in
Supplementary Figure S1C.
Gene ontology (GO) enrichment analysis of the 408
upregulated VDR target genes using GeneTrail (31) high-
lighted the role of 1a,25(OH)2D3 in the regulation of
immune response and signaling cascades and in the
positive regulation of higher-level processes (Table 1). In
particular, a positive effect of 1a,25(OH)2D3 on the pro-
duction and secretion of the cytokine interleukin (IL) 1
was implicated. The 230 downregulated genes showed as-
sociation with the negative regulation of many similar
higher-level processes as the upregulated genes. In
contrast to upregulated genes, GO terms enriched for
downregulated genes lacked categories related to
immunity and signaling, but interestingly included a
category for transcription regulator activity (Table 1).
Combining the up and downregulated genes for the en-
richment analysis did not point to additional functions
(data not shown).
In summary, we identiﬁed in THP-1 cells a set of 638
genes as primary targets of regulation by 1a,25(OH)2 D3,
and thus by VDR, that were enriched for genes that are
associated with the GO terms related to immunity and
signaling.
Genome-wide mapping of VDR binding sites
To identify genomic VDR binding sites, THP-1 cells were
treated for 40min with 1a,25(OH)2D3 or remained un-
stimulated and ChIP assays were performed with
antibodies against VDR and non-speciﬁc IgGs. Puriﬁed
chromatin samples were subjected to deep sequencing
using a Solexa GAII platform. Analysis of the resulting
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control, revealed the genome-wide landscape of the chro-
matin occupation of VDR in THP-1 cells. The reads at
various stages of the analysis are summarized in
Supplementary Table S4. In the 1a,25(OH)2D3-treated
sample the number of high-conﬁdence (FDR <1%)
peaks indicating genomic VDR binding sites was 1820,
in contrast to 1169 sites in the unstimulated sample
(Figure 1A). The total number of VDR binding sites
was 2340, with 649 (27.7%) sites common in both un-
stimulated and 1a,25(OH)2D3-treated samples and 520
(22.2%) and 1171 (50.0%) unique in unstimulated and
1a,25(OH)2D3-treated samples, respectively (Figure 1A).
The genomic locations of the 2340 binding sites are
listed in Supplementary Table S5.
VDR binding locations, grouped to unique and
common as in the Venn diagram in Figure 1A, showed
differences in their distribution to various genomic
elements (Figure 1B). Within both the unstimulated and
1a,25(OH)2D3-treated peak sets, the high-conﬁdence
peaks, compared to peaks with lower conﬁdence, were
enriched to genomic regions representing proximal
promoter and exons, and were depleted from distal
regions and introns other than the ﬁrst (Supplementary
Figure S2). However, comparing the distributions of
unstimulated and 1a,25(OH)2D3-treated peak sets
revealed that upon ligand treatment VDR favors signiﬁ-
cantly more such binding locations that are distal to genes
(>1kb upstream or >10kb downstream) and disfavors
those representing coding sequences (Figure 1B). The
shift of VDR binding from proximal to distal locations
upon ligand treatment was also highlighted by the VDR
peak proximity to TSS (Figure 1C). The density of VDR
binding proximal to the TSS diminished with decreasing
peak conﬁdence, i.e. with increasing FDR (peaks with
FDR >10% may be considered random-like), for peaks
that were either unique in the unstimulated state (left
panel) or common in both treatments (middle panel). In
contrast, such enrichment was nearly completely lacking
in the 1a,25(OH)2D3-treated cells (right panel). Together
with Figure 1B, this suggests a non-random enrichment of
VDR binding locations to gene-dense regions which, at
ﬁrst glance, appears weaker for the 1a,25(OH)2D3-
treated peak set but may in fact indicate enrichment to a
subset of genes, such as regulated genes.
Taken together, we have identiﬁed in THP-1 cells 2340
genomic VDR binding locations, a surprisingly large pro-
portion of which display at least some binding also in the
unstimulated state and not only upon 1a,25(OH)2D3-
treatment.
Table 1. GO analysis of VDR target genes
GO ID Subcategory Genes FDR
Expected Observed
Upregulated 1a,25(OH)2D3 targets
GO:0007242 Intracellular signaling cascade 29.9 55 0.0062
GO:0048518 Positive regulation of biological process 40.7 70 0.0062
GO:0048522 Positive regulation of cellular process 37.2 63 0.0111
GO:0023052 Signaling 80.0 113 0.0125
GO:0005829 Cytosol 26.0 47 0.0130
GO:0009966 Regulation of signal transduction 18.7 37 0.0130
GO:0023051 Regulation of signaling process 18.7 37 0.0130
GO:0050718 Positive regulation of interleukin-1 beta secretion 0.2 4 0.0130
GO:0080134 Regulation of response to stress 5.5 17 0.0130
GO:0050706 Regulation of interleukin-1 beta secretion 0.3 4 0.0151
GO:0050716 Positive regulation of interleukin-1 secretion 0.3 4 0.0151
GO:0007229 Integrin-mediated signaling pathway 1.1 7 0.0153
GO:0010646 Regulation of cell communication 21.6 40 0.0153
GO:0032731 Positive regulation of interleukin-1 beta production 0.3 4 0.0153
GO:0050704 Regulation of interleukin-1 secretion 0.3 4 0.0153
GO:0002376 Immune system process 21.8 40 0.0171
GO:0006950 Response to stress 35.2 57 0.0171
GO:0050702 Interleukin-1 beta secretion 0.3 4 0.0171
GO:0007275 Multicellular organismal development 57.9 84 0.0171
GO:0048583 Regulation of response to stimulus 9.4 22 0.0179
GO:0032732 Positive regulation of interleukin-1 production 0.3 4 0.0192
Downregulated 1a,25(OH)2D3 targets
GO:0051093 Negative regulation of developmental process 2.8 14 0.0011
GO:0048519 Negative regulation of biological process 20.0 41 0.0023
GO:0048523 Negative regulation of cellular process 18.3 39 0.0023
GO:0050793 Regulation of developmental process 7.3 21 0.0040
GO:0030528 Transcription regulator activity 16.2 33 0.0132
GO:0045595 Regulation of cell differentiation 5.2 16 0.0132
GO:0045165 Cell fate commitment 1.4 8 0.0137
GO:0045596 Negative regulation of cell differentiation 2.3 10 0.0141
GO:0050794 Regulation of cellular process 74.3 100 0.0141
The GO terms enriched for either up or downregulated VDR genes were identiﬁed using GeneTrail. All sub-categories with P<0.02 are listed.
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De novo binding site search using rGADEM and MotIV
R/Bioconductor packages identiﬁed the classical DR3-
type RE consensus sequence for VDR–RXR
heterodimers as the most highly enriched within 100bp
of the VDR peak summits (E-value 2.6510
12 for the
JASPAR consensus matrix MA0074.1 for RXRA::VDR).
Of note, while the JASPAR consensus has near-exclusive
T at positions 4, 12 and 13, more variability is allowed at
these positions in the de novo DR3-type REs actually
occupied by VDR in THP-1 cells (Figure 2A). However,
only 31.7% (742) of all VDR peak summits included one
or more de novo DR3-type RE. The quality of the
identiﬁed de novo DR3-type REs appears high, since the
more each of the de novo DR3-type REs resembled their
common consensus, i.e. had lower E-value, the higher was
the FE of the respective VDR peak (Pearson r=0.217,
P<310
15, Figure 2B). Hoping to identify any atypical
VDR binding consensus sequences for the remaining
68.3% (1598) of VDR peaks, we re-ran the de novo
analysis on them only, but even the most frequent consen-
sus nrGGrGswGGrrn, corresponding best to a SP1
binding site in the JASPAR database (MA0079.2, E-
value 1.0310
7), was found in 538 peaks (23.0%).
Another consensus sequence, nsAGGAAGn, was even
less frequent with 274 peaks (11.7%). The latter had
high similarity to the consensus for ETS transcription
factor family member SPI1/PU.1 (MA0080.2; E-value
8.5010
7). De novo analysis of even more focused sub-
groups, like the peaks unique to unstimulated cells, did
not reveal additional consensus sequences (data not
shown). Using a set of DR- and ER-type VDREs where
the half sites were based on the identiﬁed de novo
DR3-type RE and which covered all spacer lengths from
0 to 16 nucleotides, VDR peak sequences lacking the de
novo DR3-type RE were scanned using RSAT (37). This
scan failed to identify any VDRE with statistically signiﬁ-
cant enrichment to 100bp of the peak summit versus
the two 150bp ﬂanks of that summit region (data not
shown). It should be noted that we found no genome-
wide evidence that VDR binds to any other type of
A
B
C
Figure 1. VDR binding locations and genomic distribution in unstimulated and 1a,25(OH)2D3-treated THP-1 cells. ChIP-Seq was performed from
chromatin templates extracted from THP-1 cells that were either unstimulated or treated for 40min with 10nM 1a,25(OH)2D3.( A) Peak counts
(percentages in parenthesis) are given for locations in the unique and common categories. The ‘common’ category represents locations where both
samples had an FDR <1% peak. Peaks were considered to be at the same location when the narrower peak overlapped the wider by >50%.
(B) Distribution of VDR peaks into genomic elements. For clarity, only the most signiﬁcant P-value from the binomial test is given for each element.
Only P-values <0.005 are shown. (C) Distance to the TSS of the closest Ensembl transcript. The whole MACS peak set was divided into the
indicated FDR ranges, unique and common peak locations were deﬁned within each range and the densities of distances between each peak and the
nearest TSS plotted by peak group and FDR range. Decrease in the density at 0kb from high-conﬁdence peaks (FDR <1%) to nearly random peaks
(FDR >10%) indicates non-random proximity to TSS. Unstim, unstimulated.
9186 Nucleic Acids Research, 2011,Vol.39, No. 21VDRE than DR3. However, the possibility can not be
excluded that a few individual non-DR3 sites exist that
bind VDR.
In summary, only about a third of the genomic VDR
binding sites in THP-1 cells contained a DR3-type RE
and no common element was found to consistently
explain the presence of VDR at locations lacking the clas-
sical VDRE.
Ligand-induced genome-wide shift in DR3-type RE usage
by VDR
While the de novo DR3-type RE was, at ﬁrst look, appar-
ently relatively infrequent at sites of VDR chromatin oc-
cupation in THP-1 cells (Figure 2), on closer inspection its
presence strikingly correlated with the 1a,25(OH)2D3-de-
pendent effects on VDR binding at each location (Figure
3A). The de novo DR3-type RE was present in about 20%
of genomic VDR locations where the VDR binding in the
unstimulated sample exceeded that in the 1a,25(OH)2D3-
treated sample by >10 FE. Conversely, when the VDR
binding after a short 40min 1a,25(OH)2D3 treatment
superseded that of the unstimulated state, the percentage
of peak locations with a DR3-type RE climbed to >90%.
Furthermore, the number of de novo DR3-type REs near
the peak summit tended to associate with increased peak
FE within the common and 1a,25(OH)2D3-exclusive
peaks, but not within the unstimulated-exclusive peaks
(Figure 3B). The presence or absence of either the de
novo SPI1/PU.1 or SP1-like consensus sequences, irre-
spective of coinciding de novo DR3-type REs, did not
affect the FE of VDR peaks (data not shown).
Taken together, even without the ligand VDR occupies
many chromatin sites, but most of these do not contain a
DR3-type RE. In contrast, even a short ligand-treatment
focuses the bulk of VDR binding to sites that do contain
at least one DR3-type RE.
Proximity of VDR binding sites to 1a,25(OH)2D3 target
genes
Combining gene expression data with the genomic loca-
tions of VDR offered an avenue to explore the mechan-
isms of target gene regulation by VDR. First we mapped
the VDR binding locations into the neighborhoods of
each gene regulated by the 4h 1a,25(OH)2D3 treatment.
For the 408 upregulated genes the bulk of VDR regulation
seems to occur via sites within only 30kb from the target
gene TSS. However, a considerable proportion of regula-
tion appears to be orchestrated by VDR binding sites up
to 400kb away, especially when the sites are unique to the
1a,25(OH)2D3 treatment (Figure 4A, top panel and
Supplementary Figure S3A, top right panel). In contrast,
the 230 downregulated genes had only slight enrichment
for common and 1a,25(OH)2D3-unique peaks near the
TSS (Figures 4A, Supplementary Figures S3A and S3B,
bottom panels). The frequency of VDR peaks around the
TSS was also higher for upregulated than for down-
regulated genes (2.042.54 versus 1.052.16 peaks per
gene, Wilcoxon rank sum test P-value 5.0110
13). The
strong enrichment of 1a,25(OH)2D3-treated peaks to the
1a,25(OH)2D3-regulated gene neighborhoods conﬁrms
regulated genes as the likeliest source to the apparent de-
pletion of these peaks from the proximity of any TSS seen
in Figure 1B and 1C. Thus, VDR seems to shift from sites
in the vicinity of the TSS of non-regulated genes to the
proximity of VDR-regulated genes.
Since the presence of the de novo DR3-type REs
strongly associated with ligand-dependency of the VDR
binding (Figure 3), we investigated whether this is also re-
ﬂected by the VDR target gene regulation (Figure 4B). We
identiﬁed for each regulated gene the strongest VDR
binding location in 1a,25(OH)2D3-treated cells within
400kb of the gene TSS and deﬁned them as the most likely
regulating VDR locations (Supplementary Table S6).
These sites were further split to those in proximal
AB
Figure 2. De novo identiﬁed DR3-type REs. De novo analysis was performed on sequences 100bp of the FDR <1% VDR peak summits. (A) The
consensus DR3-type RE identiﬁed by the rGADEM de novo search is displayed in comparison to the public RXRA::VDR heterodimer consensus
sequence in the JASPAR database. Note that the de novo DR3-type RE allows more variability at certain positions than the JASPAR DR3-type
sequence. (B) Correlation between the de novo DR3-type RE E-value and the peak FE. E-value describes how perfectly each individual element
matches the common consensus (x-axis). For peaks with multiple de novo DR3-type REs, only the element with the lowest E-value was selected. The
blue line indicates the linear ﬁt with 95% conﬁdence intervals in gray, with associated Pearson correlation r and P-values given in the upper left
corner of the graph.
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400kb). If no VDR peak was present within the
400kb limit, we used from the outlying ‘desert’ the
closest peak of any FE to represent a potential very
distant regulator. Genes were divided, separately for
both up and downregulated sets, into equally sized
tertiles according to their stimulated fold change [4h
1a,25(OH)2D3 versus vehicle treatment]. The most likely
regulating VDR locations were also divided at median FE
to equally sized ‘low’ and ‘high’ VDR peak sets and
further to peaks with or without any DR3-type RE near
the peak summit. Gene counts in these 12 sub-categories
suggest that the higher the VDR peak is, the more likely it
is to strongly upregulate its target gene, especially when it
contains a DR3-type RE. As already seen in Figure 4A
and Supplementary Figure S3, strong regulation by VDR
is possible from both proximal and distal sites, but less
likely from sites beyond  400kb. Also among the genes
for which the most likely regulating VDRE was in the
‘low’ category, the proportion of DR3-type RE containing
peaks versus peaks without such sites increased toward the
high fold change genes. In contrast to upregulated genes,
the VDR peak FE or the presence of DR3-type REs
associated much less with the fold change of
downregulated target genes.
Taken together, 72% of the 408 upregulated
1a,25(OH)2D3 target genes showed VDR binding within
400kb of their TSS, while this applied only for 43% of the
230 downregulated genes.
Examples of VDR target genes
Examples of previously unidentiﬁed VDR target genes
that were upregulated by a 4h 1a,25(OH)2D3 treatment,
and for which the most likely regulating VDRE could be
easily proposed, are shown in Figure 5. SP100, a gene
encoding SP100 nuclear antigen that has been identiﬁed
as a co-repressor for transcription factors, such as ETS1
(38), is characterized by a single, strong and ligand-
dependent VDR binding region with a single de novo
DR3-type RE located in the ﬁrst intron at+0.5kb of
the gene’s TSS (a category 4 peak, Figure 5A).
Also for ELL, a gene encoding for an elongation factor
of RNA polymerase II that has also been identiﬁed as a
transcriptional co-factor for transcription factors, such as
HIF-1 (39), the single dominant VDRE is located in the
ﬁrst intron at +19.3kb of the gene’s TSS, is slightly
ligand-dependent although with considerable basal
binding and contains a DR3-type RE (Figure 5B). The
locus carries also a distal 1a,25(OH)2D3 target gene,
LRRC25 encoding the protein leucine rich repeat contain-
ing 25 of unknown function, for which the ELL VDR
binding region, located 105kb upstream of the LRRC25
TSS, appears the most likely regulator. Therefore, for the
ELL gene the VDR peak is of category 4, while for the
LRRC25 gene it is of category 5.
The third example is a complex locus containing the
three 1a,25(OH)2D3 target genes thrombomodulin
(THBD), encoding for the integral membrane protein
THBD (also called CD141) (40), CD93, encoding for the
C-type transmembrane receptor CD93 (41), and GZF1,
encoding for the GDNF-inducible zinc ﬁnger protein 1
(42) (Figure 5C). However, the microarray result for
GZF1 could not be validated by qPCR. The THBD gene
responds most effectively to 1a,25(OH)2D3 treatment,
while the strongest ligand-dependent VDR binding
region of the genomic locus is 285kb upstream of the
THBD TSS and contains eight distinct DR3-type REs
and, i.e. it is a category 5 peak. There is also one other
good genomic VDR location at 176kb upstream of the
THBD TSS, but this lacks a DR3-type RE. The locus
has still two additional, but weaker VDR binding
regions, one with a DR3-type RE and one without, at
77 and 107kb upstream of the THBD TSS, respectively.
Interestingly, there is also an unstimulated-unique VDR
AB
Figure 3. Ligand-dependent VDR occupation on the de novo DR3-type REs. The usage of the de novo DR3-type RE is strongly ligand dependent.
(A) The running mean of the difference in peak FE at VDR binding locations (x-axis;1 a,25(OH)2D3 minus unstimulated, window size 50 locations)
was plotted against the percentage of locations with the de novo DR3-type RE (y-axis). For unique peaks, the minimum FE of the whole 2340 peak
set was used as the value for the ‘missing’ sample, to represent the lower detection limit. The inset shows 3 examples of peak pairs with different
ligand effects on peak FE (a, decrease; b, no change; and c, increase). (B) The effect of the number of de novo DR3-type REs on the peak FE.
Unstim, unstimulated.
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tempting to speculate that this VDR binding site could
have a repressive role that could, together with the
strong ligand-dependent VDR binding site in the vicinity,
facilitate the relatively strong upregulation of THBD.
For all three examples the VDR binding at the sites in-
dicated with an arrow was validated from independent chro-
matin samples of unstimulated and 40min 1a,25(OH)2D3-
treated THP-1 cells by qPCR (Figure 5D). In addition to
VDR, also the presence of the heterodimerizing partner
RXR was veriﬁed from the same chromatin samples. In all
cases the 1a,25(OH)2D3 treatment signiﬁcantly increased
the amount of both VDR and RXR at the respective VDR
binding region. In addition, the upregulation by
1a,25(OH)2D3 of SP100, ELL and THBD mRNA was
conﬁrmed on independent samples (Figure 5D).
Additional examples of VDR target gene and VDR
binding site scenarios are shown in Supplementary
Figure S4. A strong double VDR peak with each a
DR3-type VDRE was found very close to the TSS of
the uncharacterized VDR target gene in chromosome 20
called open reading frame 197 (C20orf197), which also
seems to serve as regulatory site for the VDR target
genes C20orf177 and PPP1R3D (Supplementary Figure
S4A). The gene ArfGAP with SH3 domain, ankyrin
repeat and PH domain (ASAP2) is regulated by three
VDR binding sites, of which one is proximal and two
are distal (Supplementary Figure S4B). The location of
the myosin IXB (MYO9B) gene represents a similar
complex locus as that of the THBD gene, as the
MYO9B gene seems to be regulated together with the
genes OCEL1 and ABHD8 by two proximal VDR
binding sites that both contain a DR3-type RE and four
proximal sites (Supplementary Figure S4C). As examples
of downregulated VDR target genes the genes
glucosaminyl (N-acetyl) transferase 1, core 2 (GCNT1)
(Supplementary Figure S4D) and SUMO1 pseudogene 1
(SUMO1P1) (Supplementary Figure S4E) are shown
having their next VDR binding site nearly 1 Mb and
more than 300kb distant from their TSS regions, respect-
ively. Interestingly, the genomic region of SUMO1P1 also
contains the 24-hydroxylase (CYP24A1) gene, which is in
most cellular systems a strong VDR target gene with a
number of ChIP-conﬁrmed VDR binding locations
(13,43).
In summary, the eight exemplary genomic loci showed
the variation of gene regulatory scenarios ranging from a
single VDR location close to the 1a,25(OH)2D3 target
gene TSS, more complex ones with one VDR location
distal to the TSSs of one or more 1a,25(OH)2D3 target
genes and very complex ones with up to six VDR locations
clustering with multiple 1a,25(OH)2D3 target genes.
DISCUSSION
For a general understanding of the mechanisms of
1a,25(OH)2D3 signaling it is essential to monitor the
genome-wide location of VDR in relation to primary
1a,25(OH)2D3 target genes. In this study, we investigated
the sites of VDR chromatin occupancy in THP-1 human
Figure 4. VDR peak height, location at <400kb from the TSS, and the
presence of de novo DR3-type REs predicts strong upregulation of
1a,25(OH)2D3 target genes. (A) Common and treatment-unique VDR
binding sites in the neighborhoods of up- (upper panel) and
downregulated genes (lower panel). (B) The diagram on top describes
the distance categories used for selecting the most likely regulating
VDR binding site as follows (distances not to scale). For each differ-
entially expressed gene, the most likely regulating FDR <1% VDR
peak was assumed to be the largest peak (by FE) that was within
400kb of the gene TSS. The most likely regulators were further
divided into proximal and distal at 30kb to identify distance-related
differences. If no peak was within 400kb, then the closest one of any
FE was taken to represent a potential regulating site. See
Supplementary Figure S3 for the basis of the selected distance limits.
The bar graph below shows that the most likely gene regulatory VDR
binding sites for up but not downregulated genes are enriched to within
400kb of the target gene TSS and preferentially use DR3-type REs.
Here, up- and downregulated genes were separately split by fold change
into tertiles, indicated by increasing intensity of red in the triangle
below the x-axis. Peaks were split into two equal sized halves by FE
(left and right panels). Gene counts are plotted for up- (upper panel)
and downregulated genes (lower panel). The gene counts are further
split according to the presence or absence of a de novo DR3-type RE
near the summit of the most likely regulating VDR peak, as indicated
in the legend. The likely regulatory scenarios are indicated by the
circled numbers 1–12, and used as peak labels in Figure 5 and
Supplementary Figure S4. Unstim, unstimulated; Prox, proximal;
Dist, distal.
Nucleic Acids Research, 2011,Vol.39, No. 21 9189monocytes after 40min treatment with 1a,25(OH)2D3 and
in the unstimulated state using ChIP-seq, and related these
to the VDR target genes identiﬁed using microarrays from
the same cellular model 4h after ligand treatment. As
expected, GO term analysis of the 638 primary
1a,25(OH)2D3 target genes that we identiﬁed in THP-1
cells showed a clear enrichment for immune-related
genes. In particular, the positive effect of 1a,25(OH)2D3
on IL1 production and secretion was highlighted, which
ﬁts well with previous reports (44,45). However, we did
not ﬁnd IL1A or IL1B within our 638 1a,25(OH)2D3
target genes, but only the gene of the IL1 receptor antag-
onist (IL1RN) downregulated. The latter suggests that the
regulation of IL1 activity by 1a,25(OH)2D3 is indirect via
the block of the IL1 receptor. In addition, Kaler et al. (46)
suggested that in THP-1 cells 1a,25(OH)2D3 downregu-
lates the transcription factor STAT1, which is central in
IL1 regulation.
A
B
C
D
Figure 5. VDR ChIP-seq analysis of genomic loci for the 1a,25(OH)2D3 target genes SP100, ELL and THBD.I n( A–C), the peak tracks show the
unstimulated and 1a,25(OH)2D3-treated VDR peaks. The high-conﬁdence peaks are indicated as yellow-to-orange-to-red boxes, color scale signifying
FE (yellow, low FE; red, high FE), below each peak track. DR3-type REs within 100bp of VDR peak summits are indicated by blue vertical lines
below the ligand-treated VDR peak track. The gene structures are shown in blue at the bottom. Gene names in red color indicate upregulated genes
(no downregulated genes were present in the loci shown). The red arrows above the peak tracks indicate the location of the manually validated VDR
binding locations. The circled numbers above the VDR peaks indicate their category in reference to the underlined gene (see Figure 4B for details),
plus symbol and minus symbol indicating the presence or absence of a DR3-type VDRE near the peak summit. Unstim, Unstimulated. (D). ChIP
validation of VDR as well as RXR binding at sites indicated by the red arrows in A–C near the exemplary target genes SP100, ELL and THBD (bar
graphs, mean SD), and the qPCR validation of their target gene status (box plots). The 40min (ChIP) or 4h (qPCR) experiments with unstimu-
lated/vehicle (minus symbol) or 1a,25(OH)2D3 (plus symbol) treatments are indicated below the graphs.
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(47) and the 4h treatment is a reasonably short time, most
of the genes that we found in our microarray analysis
are assumed to be primary VDR target genes, i.e. VDR
should bind a regulatory chromatin region that loops to
the target gene’s TSS region. The majority (64%) of the
1a,25(OH)2D3 target genes were upregulated, which is
typical for most VDR target tissues (48,49).
Through the choice of early time points both in micro-
array and ChIP-seq experiments we aimed to detect
mainly primary VDR effects. This is in contrast to the
recent study of Ramagopalan et al. (23), who reported
VDR ChIP-seq data in HapMap lymphoblastoid cells
after a long (36h) 1a,25(OH)2D3 treatment, focusing
more on the association of VDR binding sites with
disease SNPs and aspects of human evolution.
In this study, we identiﬁed 2340 genomic sites of VDR
binding, 520 of which are exclusive to the unstimulated
THP-1 cells. By size, our set of 1820 1a,25(OH)2D3-
treated genomic VDR binding sites in THP-1 cells is com-
parable with the 2776 VDR binding sites in
1a,25(OH)2D3-treated lymphoblastoids (23), but the
overlap is only 18.2%. On the level of 1a,25(OH)2D3
target genes identiﬁed by microarray analysis the overlap
between the two cellular models is even lower at 5.6%.
Although the poor overlap may be partly explained by
differences in cutoffs when considering high-conﬁdence
peaks and target genes as well as the rather different dur-
ation of 1a,25(OH)2D3 treatment (40min or 4h versus
36h), it also suggests that VDR utilizes considerably
variant binding sites in different cells. In silico screening
for VDR binding showed an approximately 100-fold
higher number of putative REs than actually used (50).
The main regulator for the access to these sites is the or-
ganization of chromatin, which is very cell speciﬁc.
Moreover, in cells of primary origin there is a signiﬁcant
inter-individual variation in chromatin organization
and gene expression. Therefore, it is not surprising that
monocytes and lymphoblasts have a rather small over-
lap of VDR binding sites. This is fully in line with the
diversity of VDR target gene sets between different
tissues (19–22).
In the absence of ligand, VDR has been shown to
actively repress its target genes, likely via a mechanism
involving an interaction with co-repressor proteins
(17,51). Interestingly, only 14% of the 520 genomic
VDR binding locations that occur uniquely in the absence
of ligand contain a DR3-type VDRE. In contrast, up to
90% of the best 1a,25(OH)2D3-dependent VDR binding
regions contain at least one DR3-type RE. This means
that upon ligand treatment the VDR occupancy is
strongly shifted from non-DR3 locations to DR3-type
RE locations. It is possible that the non-DR3 locations
may serve as a nuclear store of VDR to be utilized
rapidly upon the introduction of the ligand, partly
substituting for the need to transport VDR into the
nucleus from outside. This mechanism may also apply to
retinoic acid and thyroid hormone receptors, but not for
the classical steroid receptors, since they do not bind to
DNA in the absence of ligand.
Interestingly, for 300 (73.5%) of the 408 upregulated
1a,25(OH)2D3 target genes we found VDR binding
within 400kb of their TSS, while this applied only for
104 (45.2%) of the 230 downregulated genes. This
suggests that the mechanisms of downregulation of
VDR target genes are rather complex and/or varied, and
may require gene-speciﬁc investigations as demonstrated
for the CYP27B1 gene (52). In this case the repressive
function of VDR is known to result from indirect inter-
action with the chromatin, via transcription factor 3, also
known as VDR interacting repressor (53). An additional
question is whether for 1a,25(OH)2D3 target genes there is
a ligand-induced derepression mechanism as described for
few other members of the nuclear receptor superfamily
(54). From the 408 1a,25(OH)2D3 target genes that we
can explain via a VDR peak within 400kb of their TSS
only 11 (2.7%) meet the derepression criteria that they
have a VDR peak in the unstimulated sample and no
peak in the 1a,25(OH)2D3-treated sample. Additional 32
genes (7.9%) can be called dominantly derepressed, since
their main peak shows only in the unstimulated sample.
This indicates that for some 10% of all 1a,25(OH)2D3
target genes a derepression mechanism may apply.
The fact that DR3-type REs are detected by our de novo
motif search as the most dominating sequence in the
genomic VDR peak regions conﬁrms earlier reports
(9,55) and the general belief in the ﬁeld that DR3-type
REs are the main type of VDREs. Nevertheless, only
31.7% of the identiﬁed VDR binding regions contain at
least one DR3-type RE, i.e. the majority of genomic VDR
binding sites do not use this type of VDRE. Since the most
dominant ligand-induced VDR binding sites are highly
enriched for DR3-type REs that, moreover, preferentially
locate to the neighborhoods of upregulated 1a,25(OH)2D3
target genes, it is likely that DR3-type REs are primarily
used in gene activation. However, this leaves the question
about the nature of VDR binding at those 68.3% of loca-
tions that lack a DR3-type VDRE. Although we could not
identify any non-DR3-type VDRE that would explain any
signiﬁcant proportion of the VDR binding, it does not
exclude the possibility that a low number of such sites
exist. Indeed, a case of repressive gene regulation via an
ER9-type VDRE has been demonstrated by Polly et al.
(17). Other possible explanations include sites where VDR
binds indirectly to genomic DNA via other transcription
factors, such as SP1, although again our de novo motif
analysis did not identify speciﬁc enrichment of other tran-
scription factor binding sites in VDR binding locations
lacking a DR3-type VDRE compared to those that had
it. A probably more likely explanation for both the
VDR-peak-less target genes as well as the target
gene-less VDR peaks comes from the recent demonstra-
tion that gene regulation by VDR is a very dynamic
process with rapid changes of VDR binding site occu-
pancy and, consequently, on the mRNA accumulation
of the 1a,25(OH)2D3 target genes (13,56). Therefore, the
time points chosen in this study represent only snap-shots
of the early actions of 1a,25(OH)2D3 and its receptor
VDR. Due to the fast dynamics of VDR binding site oc-
cupancy and resulting ﬂuctuations in target gene mRNA
amounts, it is likely that without time-course data a
Nucleic Acids Research, 2011,Vol.39, No. 21 9191considerable proportion of all transient VDR binding sites
remains unknown.
Although most of the upregulated genes may be ex-
plained by a more uniﬁed mechanism of one or multiple
VDREs, as already suggested for various VDR target
genes, such as CDKN1A (57), CYP24A1 (13,43), ALOX5
(16) and CCNC (14), we demonstrate here with three ex-
emplary genomic regions that there is quite a variation in
the gene regulatory scenarios of upregulated genes.
Genome-wide there are only about 20 genes that show,
as in the case of the SP100 gene, a single VDR location
close to the target gene TSS. More common are situations
where either one target gene has multiple VDR binding
sites in its regulatory region or, as shown for ELL and
LRRC25, a pair of closely located VDR target genes share
one or more VDR binding sites. The ﬁrst constellation we
have already demonstrated for the above mentioned VDR
target genes, while the second scenario applies for the
members of the IGFBP gene family (15). However, the
most complex regulatory situations we found in the
clusters around the VDR target genes THBD and
MYO9B, which each contains ﬁve or six VDR binding
sites of different characteristics.
In conclusion, our genome-wide characterization of
early-responding VDR binding sites close to primary
1a,25(OH)2D3 target genes identiﬁed a clear shift of
VDR binding from non-DR3 sites to DR3-type REs
upon ligand treatment. Furthermore, our data suggest
regulatory explanations for a large majority of especially
upregulated 1a,25(OH)2D3 target genes in THP-1 cells.
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